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Preface 
Angiotensin converting enzyme (ACE) is one of the key molecule in the 
renin-angiotensin system, which contribute pathophysiology of the hypertension, 
stroke, heart failure, and kidney disease. Angiotensin-converting enzyme 
inhibitors (ACE-Is) reduce the production of angiotensin II, the leading actor of 
the renin-angiotensin system (Figure).  
 
Figure  The role of renin angiotensin system in the organ pathophysiology. 
 
ACE-Is have been primarily developed and approved as the antihypertensive 
drug. A lot of studies have indicated that ACE-Is have the organ protected 
effects, and widely used in anticipation of the effects according to the various 
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guidelines, for example in Japan, hypertension (JSH2009 Hypertension 
Guidelines), stroke (Japanese Guidelines for the Management of Stroke 2009), 
heart failure (Guidelines for Treatment of Chronic Heart Failure, JCS 2010), and 
chronic kidney disease (Evidence-based Clinical Practice Guideline for CKD 
2013).  
Imidapril hydrochloride (imidapril), one of ACE-Is, has been used by a lot of 
patients with hypertension in 14 countries, since 1993 of its first approval by 
Japanese Ministry of Health, Labour and Welfare. Imidapril is an only ACE-I 
approved for the diabetic nephritis by type 1 diabetes in Japan. The 
renoprotective effects of imidapril have been reported from clinical (1) and 
non-clinical studies using diabetes animals (2-4), however, integrated 
understanding of the renoprotective effects of ACE-Is is still not enough. 
In this study, I focused on the studies on the renoprotective effects of imidapril 
beyond the antihypertensive effects using type 1 and type 2 diabetic mice, and 
also using non-diabetic nephrosis rats. 
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Chapter 1  Effects of imidapril in type 1 diabetic mice 
 
1.1 Summary 
I investigated whether the prevention of the development of diabetic 
nephropathy by angiotensin-converting enzyme inhibitors (ACE-Is) is associated 
with decreases in renal ACE activity and / or blood pressure in diabetic mice. 
C57Bl/6 mice were injected with streptozotocin (STZ, 200 mg/kg, i.v.) and 
randomized to receive either imidapril (1 and 5 mg/kg) or captopril (10 and 50 
mg/kg) or vehicle by gavage for 28 days. Each assay was performed on 8–10 
mice from each treatment. At 28 days after the start of drug treatment, imidapril 
and captopril significantly reduced blood pressure of the diabetic mice, and this 
effect of captopril was stronger than that of imidapril. On the other hand, 
inhibition of renal ACE activity by imidapril was stronger than that by captopril. 
Imidapril and captopril dose-dependently inhibited urinary albumin excretion to 
similar extents, but they failed to inhibit the renal hypertrophy and elevation of 
creatinine clearance. Total renal ACE activity was significantly reduced in 
diabetic mice, but immunohistochemical localization of ACE was intensive in the 
vasculature and glomeruli of the diabetic kidney. In conclusion, both effects on 
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blood pressure and renal ACE activity may be involved in the prevention of 
development of diabetic nephropathy by imidapril and captopril in STZ-induced 
diabetic mice. The data suggest that the degrees of contribution of their effects 
on blood pressure and renal ACE activity to the inhibition of urinary albumin 
excretion may be different between the two ACE-Is. 
 
1.2 Introduction 
ACE-Is have been shown to preserve the renal function in diabetic patients with 
nephropathy (5-8). In experimental rodent models of diabetes mellitus, 
advanced lesions were reported to mimic some findings of the early-stage 
clinical diabetic nephropathy (9, 10) and ACE-Is have also been shown to 
attenuate renal diseases (5, 10). In human (11) and animal (12, 13) studies, 
diabetic nephropathy is commonly associated with hypertension. It is well 
established that hypertension aggravates diabetic nephropathy (14). However, 
as shown in a meta-analysis of clinical trials, ACE-Is reduce proteinuria and 
attenuate the progression of renal failure in patients with diabetic nephropathy 
more effectively than treatment with conventional antihypertensive drugs such 
as Ca2+ channel antagonists and β-adrenoceptor antagonists (15, 16). Moreover, 
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ACE inhibition seems to be effective in slowing down the progression of human 
diabetic nephropathy through mechanisms not related to blood pressure (6, 17, 
18). Up-regulation of the local tissue renin–angiotensin system in response to 
injury has been shown in a variety of renal diseases (19-21). These findings 
leave unanswered the question whether the renoprotective effect of an ACE-I 
was directly related to the inhibition of angiotensin II or to its eventual 
antihypertensive effect. In the present study, I investigated the effects of ACE-Is, 
imidapril and captopril on renal disease, ACE activity and blood pressure in mice 
with diabetes induced by STZ. In addition, I applied an immunohistochemical 
technique to determine the localization of ACE in the kidney of diabetic mice. 
 
1.3 Materials and Methods 
1.3.1 Chemicals 
Imidapril (CAS No. 89396-94-1) was synthesized in Tanabe Seiyaku (Saitama, 
Japan). Captopril (CAS No. 62571-86-2) and STZ (CAS No. 18883-66-4)were 
purchased from Sigma Chemical (St. Louis, MO, USA). 
1.3.2 Animal experiments 
Nine-week-old male C57Bl/6 mice (Japan CLEA, Tokyo, Japan) were housed 
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in a specific pathogen-free facility and were maintained on standard mouse 
chow and tap water ad libitum. Under light ether anesthesia, the mice were 
injected into the tail vein with a bolus injection of 200 mg/kg of STZ dissolved in 
citrate buffer (pH 4.8). After 4 days, induction of diabetes was confirmed by 
measurement of the tail blood glucose level using the glucose oxidase method 
(New Blood-Sugar test; Boehringer Mannheim, Mannheim, Germany), and 
hyperglycemic mice with glucose levels over 300 mg/dL were used. The diabetic 
mice were randomly divided into the following five groups (10 animals in each 
group) treated with vehicle (distilled water), imidapril (1 and 5 mg/kg), and 
captopril (10 and 50 mg/kg). Ten non-diabetic mice, which had not been injected 
with STZ, were treated with vehicle. Vehicle or each drug in a volume of 10 
mL/kg was given orally to mice by gastric gavage in the morning once a day. 
Body weight was measured weekly. The systolic blood pressure (SBP) and heart 
rate of each mouse were measured by the tail-cuff method (UR-5000; Ueda, 
Tokyo, Japan) before and after the 28-day period of treatment. Blood glucose 
was measured before treatment and after 14 and 28 days of treatment. On the 
29th day, the mice in each group were anesthetized with ether and blood 
samples were taken from the abdominal aorta. Bilateral kidneys were rapidly 
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removed and weighed. Half the middle portion of the left kidney was immediately 
fixed for 60 min with methacarn solution for the estimation of glomerular 
morphometry, or embedded in the Tissue Tek (Miles, Elkhart, IN, USA), and 
frozen for immunohistochemical analysis of ACE. The rest of the kidney was 
frozen in liquid nitrogen and stored at -80℃ until the measurement of ACE 
activity. 
1.3.3 Measurements of urinary albumin level and renal function 
On Days 14 and 28, the mice were detained in individual metabolic cages for 
24 h for urine collection. The urine volume was measured gravimetrically, and 
urinary albumin concentrations were determined with an enzyme-linked 
immunosorbent assay (ELISA) using a murine microalbuminuria kit (Albuwell M; 
Exocell, Philadelphia, PA, USA). Renal function was evaluated by calculating 
creatinine clearance (Ccr, mL/min/100 g body weight). The plasma and urinary 
creatinine levels were measured by an enzymatic method (CRE; Mizuho medy, 
Saga, Japan) using the autoanalyzer Hitachi 7150 (Hitachi, Tokyo, Japan). The 
blood (serum) urea nitrogen levels were measured by using the autoanalyzer. 
1.3.4 Morphometric analysis of glomerular 
Half middle portion of left kidney was fixed with methacarn solution, and 
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embedded in paraffin. Four-micrometer-thick slices were stained with periodic 
acid-Schiff (PAS). In PAS stained section of the renal cortex, the glomerular tuft 
area was determined by the total glomerular area minus the urinary space area 
and the urinary recesses, as previously described (10). More than 30 glomeruli 
were counted per kidney and the average was used for analysis. 
1.3.5 Measurement of renal ACE activity 
Assay of ACE activity was performed on 8–10 mice from each group. Renal 
ACE activities were measured with tissue samples taken on the 29th day of 
treatment by using a fluorometric assay described by Cheung and Cushman 
(22). The ACE activity was calculated as nanomoles of His–Leu generated per 
mg tissue weight/hour. 
1.3.6 Immunohistochemistry for ACE 
The frozen renal tissues of five randomly selected mice in the non-diabetic and 
diabetic groups were cut into 5-mm-thick slices, and mounted on slides. To 
detect ACE, the slices were fixed in acetone, and incubated with 1 mg/mL of the 
anti-human ACE monoclonal antibody (9B9; Chemicon, Temecula, CA, USA) for 
60 min at room temperature. The samples were subsequently incubated with 
rabbit anti-mouse immunoglobulin (IgG), and then with a mouse alkaline 
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phosphatase anti-alkaline phosphatase immune complex. The slide was washed 
in Tris (pH 7.6) -buffered saline after each step. Bound alkaline phosphatase 
was visualized by new fuchsin and levamisole to yield a red reaction product. All 
sections were counterstained with hematoxylin. 
1.3.7 Statistical analysis 
Data are expressed as means ± standard errors of the mean (S.E.M.).  
Statistical analysis was done by SuperANOVA (Abacus Concepts, Berkeley, CA, 
USA) on a Mackintosh computer. Comparison between non-diabetic and 
diabetic mice was performed by Student’s t-test. Differences among the diabetic 
groups were analyzed by using one-way analysis of variance (ANOVA) followed 
by the Tukey–Kramer test for multiple comparison. A p value less than 0.05 was 
considered statistically significant. 
 
1.4 Results 
In the diabetic mice, two mice in imidapril (5 mg/kg)-treated group and one 
mouse in captopril (50 mg/kg)-treated group died spontaneously between the 
21st and 29th day of treatment. No mice in the other experimental groups died 
during the period of treatment. 
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1.4.1 Body weight, blood glucose and blood pressure 
Diabetes was associated with reduced weight gains and increased plasma 
glucose levels which were not influenced by the imidapril and captopril 
treatments (Table 1.1). Figure 1.1 shows SBP of each group at 28 days after the 
start of drug treatment. The SBP of the diabetic group was slightly, but not 
significantly higher than that of the non-diabetic group. The SBP was 
significantly reduced by treatment with either imidapril or captopril. The blood 
pressure lowing by captopril was greater than that by imidapril. 
1.4.2 Renal hypertrophy and function 
Urine volume and kidney weight were increased in the diabetic group 
compared with non-diabetic group (Table 1.2). Treatment with imidapril and 
captopril did not influence these parameters. Glomerular tuft areas in diabetic 
mice were increased (Table 1.2), but morphometric analysis showed no 
apparent mesangial sclerosis in diabetic mice. Blood urea nitrogen and serum 
creatinine were not affected in the diabetic group (31 ± 1 and 0.09 ± 0.01mg/dL, 
respectively) compared with non-diabetic group (30 ± 1 and 0.10 ± 0.00 mg/dL, 
respectively). 
Ccr increased clearly in the diabetic group, but showed no further change in the 
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mice treated with either imidapril or captopril (Table 1.2). 
1.4.3 Effects on urinary albumin excretion 
The urinary albumin excretion level of each group on Day 28 is shown in Figure 
1.2. The urinary albumin excretion level of the diabetic group was higher than 
that of the non-diabetic group. The urinary albumin excretion level was 
dose-dependently reduced by treatment with either imidapril or captopril. This 
urinary albumin excretion-reducing effect was not different between the 
treatments with the ACE-Is. There were no significant differences in urinary 
albumin excretion levels on Day 14 among the diabetic mice treated with drugs. 
1.4.4. Activity and immunolocalization of ACE 
Renal ACE activity was decreased significantly in the diabetic group compared 
with the non-diabetic group, and was further decreased by treatment with 
imidapril and captopril. The ACE activity of the imidapril-treated groups was 
much lower than that of the captopril-treated groups (Figure 3). 
In the non-diabetic mice, immunoreactivity for ACE was slightly present in the 
endothelium of the renal vein and glomeruli (Figure 4A and C). On Day 29, both 
the endothelium of renal arteries and the glomeruli in the diabetic group were 
intensely immunoreactive to the ACE anti-body (Figure 4B and D), but the 
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intensity of staining for ACE in the tubules was slightly decreased. No 
immunoreactivity was noted when the ACE antibody was replaced with the 
non-immune IgG negative control. 
 
1.5 Discussion 
The present study demonstrates two major findings. First, the ACE-Is imidapril 
and captopril equally prevented the elevation of urinary albumin excretion levels 
in STZ-induced diabetic mice with high blood glucose, but showed differences in 
the potency of reducing blood pressure and ACE activity. Second, renal ACE 
activity was significantly decreased in the diabetic group compared with the 
non-diabetic group, but on immunohistochemical analysis, both the endothelium 
and the glomeruli of the diabetic kidney were intensely immunoreactive to the 
ACE antibody. 
Imidapril showed a dose-dependent inhibitory effect on the elevation of urinary 
albumin excretion levels in a pattern identical to the effect seen with captopril in 
the diabetic mice. Systemic hypertension is a well-known cause of progressive 
renal injury in both humans (11) and experimental animals (12, 13). In the 
present study using the diabetic mice, the antihypertensive efficacy of captopril 
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was stronger than that of imidapril. Therefore, the hypotension did not only 
account for the inhibitory effects of these ACE-Is on the urinary albumin 
excretion level in diabetic mice. On the other hand, inhibition of renal ACE 
activity by imidapril was greater than that by captopril in the diabetic mice. The 
reason for this difference was not clear, but some ACE-Is, which equally 
inhibited circulating ACE, had shown major differences in affinity for tissue ACE 
(23-25). Thus, our observations suggest that the renoprotective effects of the 
ACE-Is may be attributable to both hypotension and inhibition of renal ACE 
activity. 
Another explanation for the effects of the ACE-Is on the urinary albumin 
excretion level is the amelioration of permeability properties of the glomerular 
basement membrane. The permeability of glomerular basement membrane is 
dependent on both size-selectivity and charge-selectivity. Morelli et al. (26) 
reported that ACE inhibition diminished glomerular permeability to proteins by 
enhancing barrier size-selectivity measuring by the dextran fractional clearance 
in humans with diabetic glomerulopathy. 
Angiotensin II has a stimulatory effect on transforming growth factor-ß 
production (27, 28) and there is evidence that angiotensin II increases 
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extracellular matrix production in the diabetic kidney (29, 30). These results 
suggest that one of these effects may be involved in the therapeutic effect of 
ACE-Is in diabetic nephropathy. ACE was shown to be the rate-limiting step for 
the biological action of the renin–angiotensin system (31, 32). In addition, tissue 
ACE activity correlates positively with the tissue angiotensin II levels (33). 
Therefore, to explore the role of ACE, I compared the activity and 
immunolocalization of renal ACE in normal and diabetic mice. As a result, renal 
ACE activity in the diabetic mice was significantly lower than that in normal mice. 
However, ACE immunostaining intensity was enhanced in the glomeruli and 
renal vasculature of the diabetic kidney. Thus, I speculate that in these sites in 
diabetes, the increase in local tissue ACE leads to increased local angiotensin II. 
These results, which coincide with the results of a study on STZ-induced 
nephropathy in rats (19), suggest that the findings of reduced whole kidney ACE 
activity do not necessarily imply a uniform reduction of tissue ACE activity in 
those sites e.g. glomeruli and vasculature., and that the intrarenal ACE may be 
involved in the development of nephropathy in STZ-induced diabetic mice. 
I showed in this study that imidapril and captopril reduced the increase in the 
urinary albumin excretion level, but did not affect Ccr and renal hypertrophy. 
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These results are consistent with previous reports (13, 34), which investigated 
the effects of ACE-Is administered for 4 or 8 weeks in STZ-induced diabetic 
models. However, some researchers (10, 29), who treated the animals with 
ACE-Is for 12 and 24 weeks, found that the ACE-Is inhibited glomerular 
hyperfiltration and/or renal hypertrophy. Especially, Sassy-Prigent et al. (10) 
showed that the ACE-Is inhibited the increase in urinary albumin excretion but 
not the renal hypertrophy at 4 weeks in STZ-induced diabetic rats. Thus, I 
speculate that the lack of effects of the ACE-Is on increased creatinine clearance 
and renal hypertrophy may be due to the duration of treatment in our study. 
Furthermore, using morphometric techniques, I found that the glomerular tuft 
areas were increased, but mesangial sclerosis did not occur in diabetic mice. I 
showed that the blood urea nitrogen and serum creatinine levels were not 
increased in diabetic mice. These results suggest that mice, 4 weeks after the 
STZ injection, may be in early stage of diabetic nephropathy. Further studies are 
needed to clarify the influence of other variables known to modulate the ACE. 
In conclusion, I found that the ACE-Is in doses equipotent for reduction of the 
increase in urinary albumin excretion level showed different effects on blood 
pressure and renal ACE activity. Our results in the present study support the 
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concept that the prevention by ACE-Is of the development of nephropathy in 
experimental diabetes may involve both the decreased blood pressure and 
inhibition of renal ACE activity. In addition, the data suggest that the ACE-Is 
imidapril and captopril may exhibit major differences in their mechanisms of 
urinary albumin excretion inhibition in diabetic mice. 
 
1.6 Publication 
 The study in this chapter was published as “Effects of imidapril and captopril on 
streptozotocin-induced diabetic nephropathy in mice” in the European Journal of 
Pharmacology, 2000, 398: 381-7. 
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1.7 Figures and tables 
 
Figure 1.1 Systolic blood pressure (SBP) in the non-diabetic, diabetic, diabetic + 
imidapril (1 and 5 mg/kg) and diabetic + captopril (10 and 50 mg/kg) groups after 
the 28-day treatment in streptozotocin-induced diabetic mice. Values are means 
+ S.E.M. n=8–10. **P<0.01 compared with the diabetic group. ##P<0.01 
compared with the diabetic imidapril (1 mg/kg) group. 
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Figure 1.2. Urinary excretion of albumin (UAE) in the non-diabetic, diabetic, 
diabetic + imidapril (1 and 5 mg/kg) and diabetic + captopril (10 and 50 mg/kg) 
groups after the 28-day treatment in streptozotocin-induced diabetic mice. 
Values are means + S.E.M. n=9–10. **P<0.01 and *P<0.05 compared with the 
diabetic group. 
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Figure 1.3. Renal angiotensin-converting enzyme (ACE) activity in the 
non-diabetic, diabetic, diabetic + imidapril (1 and 5 mg/kg) and diabetic + 
captopril (10 and 50 mg/kg) groups after the 28-day treatment in 
streptozotocin-induced diabetic mice. Values are means + S.E.M. n=8–10. 
**P<0.01 compared with the diabetic group. ##P<0.01 compared with the 
diabetic + captopril (50 mg/kg) group. 
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Figure 1.4. Immunohistochemical localization of angiotensin-converting enzyme 
in the renal arteries (A and B) and glomeruli (C and D) sacrificed on the 33rd day 
after streptozotocin treatment. A and C: Sections from the kidney of the 
non-diabetic group. B and D: Sections from the kidney of the diabetic group. 
Bar indicates 100 µm. 
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Table 1.1 Body weight and blood glucose concentration of 
streptozotocin-induced diabetic mice before and after treatment with 
angiotensin-converting enzyme inhibitors 
 
The non-diabetic mice were treated with vehicle. The diabetic mice were 
randomly divided into the following five groups treated with vehicle (distilled 
water), imidapril (1 and 5 mg/kg), and captopril (10 and 50 mg/kg). Values are 
means ± S.E.M. **P<0.01 compared with the diabetic group. 
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Table 1.2 Urine volume, kidney weight and creatinine clearance after the 28-day treatment with angiotensin-converting 
enzyme inhibitors in streptozotocin-induced diabetic mice 
 
The non-diabetic mice were treated with vehicle. The diabetic mice were randomly divided into the following five groups 
treated with vehicle (distilled water), imidapril (1 and 5 mg/kg), and captopril (10 and 50 mg/kg). Values are means ± S.E.M. 
n=8–10. Kidney weight indicates total weight of left and right kidneys. **P<0.01 compared with the diabetic group.
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Chapter 2  Effects of imidapril in type 2 diabetic mice 
 
2.1 Summary 
I investigated the renoprotective effects of an ACE-I, imidapril in a diabetic 
animal model. I used BKS.Cg-+Leprdb/+Leprdb (db/db) mice, a genetic animal 
model of obese type 2 diabetes. Diabetic db/db mice suffered from glomerular 
hyperfiltration, albuminuria and hypoalbuminemia. Oral administration of 5 
mg/kg/day of imidapril for 3 weeks suppressed renal hyperfiltration, reduced 
albuminuria and normalized hypoalbuminemia. Imidapril did not influence body 
weights, blood pressure or blood glucose concentrations in db/db mice. Urinary 
excretion of heparan sulfate (HS) in non-treated 11-week-old db/db mice was 
significantly lower than that in age-matched non-diabetic db/+m mice. HS is a 
component of HS proteoglycans, which are present in glomerular basement 
membranes and glycocalyx of cell surfaces. Reduced urinary HS excretion 
indicated glomerular HS loss in db/db mice. Imidapril increased urinary excretion 
of HS to concentrations observed in non-diabetic BKS.Cg-m+b/+Leprdb (db/+m) 
mice, indicating that imidapril prevented the loss of renal HS. These results 
suggest that imidapril ameliorates renal hyperfiltration and loss of renal contents 
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of HS. Improvement of filtration function and maintenance of HS, which is an 
important structural component of glomeruli, may contribute to renoprotective 
effects of imidapril. 
 
2.2 Introduction 
ACE-Is have been shown to preserve renal function in diabetic patients with 
nephropathy (5-8). As shown in meta-analyses of clinical trials, ACE-Is reduce 
proteinuria and attenuate the progression of renal failure in patients with diabetic 
nephropathy more effectively than treatment with conventional antihypertensive 
drugs, such as Ca2+ channel blockers or β-adrenoceptor antagonists(15, 16) 
(5,6). Moreover, ACE inhibition appears to be effective in slowing the 
progression of human diabetic nephropathy through mechanisms that are not 
related to blood pressure (6, 17, 18) . Up-regulation of local tissue renin–
angiotensin system has been shown in a variety of renal diseases (19-21). 
Imidapril, an ACE-I, has been used as an antihypertensive drug, and is indicated 
for diabetic nephropathy caused by type 1 diabetes. Clinical usage of imidapril 
has been well reviewed by Robinson et al. (1) Preclinical studies have 
suggested that imidapril reduces proteinuria and renal lesions in type 1 (Chapter 
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1) and type 2 (2-4) diabetic nephropathy models. However, the renal protective 
mechanisms of ACE-Is, including imidapril, are not fully understood. In the 
present study, I investigated the effects of imidapril on renal function and urinary 
excretion of heparan sulfate (HS), which is a glomerular structural component of 
glomeruli, in a type 2 diabetic model, db/db mice. 
 
2.3 Materials and Methods 
2.3.1 Chemicals 
Imidapil (CAS No. 89396-94-1) was synthesized at Mitsubishi Tanabe Pharma 
(Osaka, Japan). 
2.3.2 Animals 
Male db/db mice and their non-diabetic controls, db/+m mice, were obtained 
from CLEA Japan (Tokyo, Japan). They were individually housed in 
polycarbonate cages (3600 M, Tecniplast, Milan, Italy) throughout the 
experiments. They were allowed free access to standard laboratory chow, 
CRF-1 (Oriental Yeast, Tokyo, Japan), and tap water. The animal room was 
controlled for temperature (23 ± 2 ℃), humidity (55 ±15%) and light (12-h light: 
dark cycle). All animals used for the experiments were at 8 weeks of age after 1 
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week of acclimation. 
2.3.3 Experimental procedures 
Sixteen diabetic db/db mice divided into two experimental groups that were 
matched for SBP and blood glucose concentrations. Diabetic db/db mice 
received imidapril (5 mg/kg/day p.o.) or purified water once daily for 3 weeks. 
Eight non-diabetic db/+m mice also received purified water once daily for 3 
weeks. SBP was determined using the tail-cuff method (UR-5000; Ueda, Tokyo, 
Japan) before and 20 days after treatment with imidapril. Body weight and blood 
glucose were monitored weekly. Urine was collected before and 22 days after 
treatment with imidapril. At the end of the experimental period, the mice were 
sacrificed by exsanguination from the abdominal aorta under ether anesthesia. 
The blood was centrifuged, and the obtained plasma was stored at 30℃ until 
further analyses. Both kidneys were removed and weighed. 
2.3.4 Measurements 
Plasma glucose, urinary albumin and HS concentrations were determined 
using commercially available kits (New Blood Sugar Test, Boehringer Mannheim, 
Mannheim, Germany; Mouse Albumin ELISA Kit, Shibayagi, Gunma, Japan; and 
Heparan Sulfate ELISA Kit, Seikagaku Corporation, Tokyo, Japan, respectively). 
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Plasma and urinary creatinine concentrations were determined using an 
autoanalyzer (Hitachi 7070, Hitachi, Tokyo, Japan). Urinary excretions of 
albumin and HS were calculated according to the equations: urinary excretion at 
an initial period = urine volume × urinary concentration / body weight, and urinary 
excretion at the end of the experiments = urine volume × urinary concentration / 
kidney weight. Compared with db/+m mice, urinary excretion was lower and 
body weight was significantly higher in diabetic db/db mice at the end of the 
experiment. Therefore, kidney weight was used as a denominator instead of 
body weight to avoid overestimation of their excretory functions.  
2.3.5 Statistical analysis 
Data are expressed as means ± S.E.M. Statistical analysis was conducted by 
the closed testing procedure. Comparisons of the difference between 
non-diabetic db/+m control and diabetic db/db mice were made by Student’s 
t-test first. After that, effects of imidapril in db/db mice were compared between 
with or without treatment db/db mice by Student’s t-test. A p value less than 0.05 
was considered statistically significant. 
 
2.4 Results 
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Time course of body weight, blood glucose concentrations and SBP is shown in 
Figure 2.1. Compared with db/+m control mice, body weight was significantly 
higher, blood glucose concentrations were greatly higher, and SBP was slightly 
but significantly lower in db/db mice. These significant differences were 
maintained throughout the experiments and were not affected by treatment with 
imidapril (Figure 2.1). Urinary excretions of creatinine and HS per body weight in 
db/db mice were not different from those in db/+m control mice at 8 weeks of age 
(Table 2.1). However, urinary excretion of albumin per body weight in db/db mice 
was greater than that in db/+m control mice (Table 2.1). 
After 22 days of treatment with 5 mg/kg of imidapril, kidney weights and plasma 
creatinine concentrations were almost similar in all experimental groups (Figure 
2.2). Urine volume and creatinine clearance (Ccr) in db/db mice were greater 
than those in db/+m control mice. Imidapril significantly corrected hyperfiltration 
as indicated by the increased Ccr observed in db/db mice, but it did not affect 
urine volumes (Figure 2.2). 
Urinary excretion of albumin in db/db mice was much higher than that in db/+m 
mice, and imidapril tended to decrease urinary excretion of albumin in db/db 
mice (p=0.07, Figure 2.3). Plasma albumin concentrations in db/ db mice was 
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similar to those in db/+m mice, and imidapril increased these concentrations 
significantly. Urinary excretion of HS in db/db mice was significantly lower than 
that in db/+m mice, and the imidapril-treated group showed significantly higher 
HS excretion than nontreated db/db mice (Figure 2.3). Plasma HS 
concentrations in db/db mice were slightly but significantly higher than those in 
db/+m mice, and imidapril did not affect these concentrations (Figure 2.2). 
 
2.5 Discussion 
Previous studies have indicated that imidapril inhibits the progression of renal 
diseases independently of its antihypertensive effects (3). They demonstrated a 
reduction in proteinuria, leading to diminished renal histological changes 
following treatment with imidapril. Furthermore, Nawano et al. reported that 
imidapril enhances the expression of insulin receptor substrate proteins (2). 
However, few studies indicate which molecules in renal structures are influenced 
by imidapril. 
In the present study, imidapril ameliorated hyperfiltraion with a tendency of 
reduction in albuminuria accompanied by an increase in plasma albumin 
concentration, confirming the renoprotective effects of imidapril in db/db mice 
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during the hyperfiltration period. It is well known that clinical use of ACE-Is, 
including imidapril, maintains glomerular filtration function for long period of time 
in patients with renal diseases. Slight decrease in glomerular filtration has also 
been demonstrated during the early phase of treatment with ACE-Is (35). Taken 
together, these data suggest that ACE-Is may reduce the excessive glomerular 
filtration load of effective glomeruli. 
Plasma HS concentrations in db/db mice were slightly but significantly higher 
than those in db/+m control mice at 11 weeks of age. Although the underlying 
mechanisms are not clear, the higher HS concentrations may be related to the 
larger body mass of db/db mice, because HS-containing proteins are expressed 
ubiquitously (36). The higher turnover rate of systemic HS may be another 
contributing factor. On the other hand, urinary excretion of HS in 11-week-old 
db/db mice was significantly lower than that in age-matched db/+m mice, surely, 
reflecting glomerular HS contents rather than circulating HS concentrations. 
Moreover, these results suggest that HS contents in the kidneys of db/db mice 
may be markedly decreased. Decreased urinary excretion of HS in 11-week-old 
db/db mice may reflect HS loss in glomeruli as a result of hyperglycemia and/or 
hyperfiltration. Glomerular structures may be injured during the early stages of 
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diabetes in db/db mice. Imidapril prevented the reduction in urinary excretion of 
HS without affecting plasma HS concentrations. These results suggest that 
imidapril maintains glomerular HS contents, but the precise mechanisms remain 
unclear. 
Although the exact reasons for decrease of HS in glomeruli remain unclear, 
reduction of the expression of HS-containing proteins and accelerated 
enzymatic deglycosylation of HS proteoglycans are some of the possibilities. 
Recently, van den Hoven et al. (37) reported that glomerular heparanase activity 
was increased in adriamycin nephropathy in rats. 
Furthermore, a clinical report showed a decline of HS in glomerular basement 
membranes without changes in the contents of core protein, agrin, in patients 
with diabetes (38). 
In the present study, I did not determine glomerular heparanase activities or 
contents of HS-containing proteins. However, aforementioned reports suggest 
that accelerated enzymatic deglycosylations of HS-proteoglycans could be 
involved. Further studies are required to determine the precise protective 
mechanisms of imidapril in terms of renal HS containing proteins. Nevertheless, 
urinary HS may be a convenient marker for the condition of glomerular HS 
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containing proteins. Imidapril corrected glomerular filtration function and may 
protect renal structures at least in part by maintaining contents of HS containing 
proteins. 
Since Brenner et al. (39) proposed the hypothesis of the charge barrier several 
decades ago, many researchers have believed that renal glomerular molecular 
selectivity was comprised two factors: the size barrier and the charge barrier. HS 
has been considered as an important component of the renal charge barrier, and 
early studies have established the importance of HS proteoglycans and their 
glycosaminoglycan chains as components of charge barrier (40). However, 
some studies have reported no proteinuria following the deletion of HS 
containing proteins in glomeruli (41, 42). Moreover, clinical findings also deny a 
relationship between severity of proteinuria and HS proteoglycans (43). Recently, 
HS proteoglycans have been recognized as the molecules involved in cellular 
signals in podocytes and other cell types (44). Hence, the putative roles of 
HS-containing proteins may have shifted from charge barrier molecules to the 
signal transducers of glomerular epithelial cells. Imidapril has functional 
renoprotective effects involving correction of glomerular filtration function, and it 
may also have structural effects that protect filtration surface structures by 
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maintaining HS containing proteins. 
The relationship of angiotensin II signals and HS contents in glomeruli is still 
unclear. There is a report that angiotensin II type receptor-mediated 
HS-proteoglycans production in SV40 transformed podocyte (45), but the 
above-mentioned in vivo observations indicate that the most important factor is 
not whole protein contents but HS glyco-chain loss. However, further 
investigations are required to determine the relationship between angiotensin II 
signals and HS contents. 
In this study, imidapril improved hyperfiltration and protected against HS loss, 
as indicated by decreased urinary excretion of HS, in diabetic db/db mice. These 
data suggest that both functional and structural mechanisms play a significant 
role in the renoprotective effect of imidapril. 
 
2.6 Publication 
 The study in this chapter was published as “Involvement of heparan sulfate in 
the renoprotective effects of imidapril, an angiotensin-converting enzyme 
inhibitor, in diabetic db/db mice” in the Journal of Receptors and Signal 
Transduction, 2014, 34: 21-5. 
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2.7 Figures and tables 
 
Figure 2.1 Time course of body weight, blood glucose concentrations and 
systolic blood pressure (SBP). □, db/tm; ○, db/db; ●, db/db treated with imidapril; 
Means ± S.E.M. n=8. ##p<0.01 compared with db/db control using Student’s 
t-test.  
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Figure 2.2 Effects of 3-week administration of imidapril on kidney weight, plasma 
creatinine concentration, urine volumes per kidney weight (UV/kidney weight), 
and Ccr per kidney weight in 11-week-old mice. Mean + S.E.M. of eight animals. 
Each p Value was calculated using Student’s t-test. 
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Figure 2.3 Effects of 3-week administration of imidapril on urinary excretion of 
albumin (UalbV) and heparan sulfate (UHSV) per kidney weight and plasma 
concentration of albumin and HS in 11-week-old mice. Mean + S.E.M. n=8. Each 
p Value was calculated using Student’s t-test. 
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Table 2.1 Urinary parameters of 8-week-old mice before treatment with imidapril. 
 
UcreV/bwt, UalbV/bwt, and UHSV/bwt indicate urinary excretion of creatinine, 
albumin, and heparan sulfate per body weight, respectively. Means ± S.E.M. n=8. 
##p<0.01, as compared with db/db using Student’s t -test. 
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Chapter 3  Effects of imidapril in nephrosis rats without 
diabetes 
 
3.1 Summary 
I investigated the effect of angiotensin-converting enzyme inhibition on 
spontaneous nephrosis in Dahl salt-sensitive (Dahl/S) rats. Dahl/S rats fed on a 
normal sodium diet spontaneously developed nephrosis and mild hypertension 
from a young age. In young Dahl/S rats, an ACE-I, imidapril, attenuated the 
development of proteinuria accompanied by a decrease in blood pressure. 
Methylprednisolone, a potent therapeutic agent for proteinuria, did not affect the 
development of nephrosis. An angiotensin type 1 (AT-1) receptor antagonist, 
losartan, but not a Ca2+ channel blocker, verapamil, inhibited the development of 
nephrosis while both agents decreased blood pressure to a similar extent as 
imidapril. In mature Dahl/S rats, imidapril suppressed not only the development 
of proteinuria but also the glomerular lesions. It is concluded that the 
development of spontaneous nephrosis in Dahl/S rats is mediated by 
angiotensin II. 
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3.2 Introduction 
Dahl salt-sensitive Dahl/S. rats are genetically predisposed to develop 
hypertension when fed on a high salt diet (46). Dahl/S rats have been used as a 
model of salt-sensitive hypertension. Salt-induced hypertension in Dahl/S rats 
leads to renal damage (47), and there are slight morphological changes in 
Dahl/S rats fed on a normal sodium diet. Other investigators have demonstrated 
that the kidneys of Dahl/S rats are abnormal.  Sterzel et al.(48) demonstrated 
that young Dahl/S rats had proteinuria which was not prevented by a low sodium 
diet. O’Donnell et al. (49) demonstrated that Dahl/S rats fed on standard 
laboratory chow had proteinuria and hyperlipidemia, and developed focal and 
segmental glomerulosclerosis. Abnormalities of lipid metabolism in Dahl/S rats 
also have been reported (50-53). Although Dahl/S rats develop nephrosis 
spontaneously, there are few studies about nephrosis in Dahl/S rats fed on a 
normal sodium diet. The present study was undertaken to clarify the role of 
angiotensin II in the development of spontaneous nephrosis in Dahl/S rats. 
 
3.3 Materials and Methods 
3.3.1 Drugs 
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Imidapril (CAS No. 89396-94-1) and losartan (CAS No. 124750-99-8) were 
synthesized by Tanabe Seiyaku (Osaka, Japan). Methylprednisolone (CAS No. 
83-43-2) and verapamil (CAS No. 152-11-4) were purchased from Sigma (St. 
Louis, MO, USA). Each compound was dissolved in purified water and 
administered p.o. once a day at noon. 
3.3.2 Animals 
Male Dahl salt-resistance (Dahl/R) rats and Dahl/S rats were purchased from 
SEAC Yoshitomi (Fukuoka, Japan). These strains of Dahl rats originated in 
Møllegaards Avlslaboratorium (Ejby, Denmark). The rats were given standard 
laboratory chow containing 0.39% (w/w) of sodium (CE-2, CLEA, Tokyo, Japan) 
and tap water was available ad libitum throughout the experiments. Four rats 
were housed in one cage except during the periods of urine collection.  
3.3.3 Experimental procedure 
3.3.3.1 Effects of imidapril and methylprednisolone on nephrosis in young 
Dahl/S rats  
A total of 32 Dahl/S rats aged 4 weeks were divided into four groups. Animals in 
each group were daily given either vehicle, imidapril (0.5 or 2 mg/kg) or 
methylprednisolone (2 mg/kg) for 15 days from the age of 5 weeks. Eight 
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age-matched Dahl/R rats were given vehicle and served as a reference. The 
24-h urine collection was performed 5 days before and 1, 8 and 15 days after the 
start of drug administration. Urinary excretion of protein (UproV) was calculated 
from the urinary protein concentration and urine volume. SBP)was measured by 
the tail-cuff method (UR-5000, Ueda, Tokyo, Japan) 3 days before and 4 and 11 
days after the start of drug administration. Blood pressure was measured in the 
morning just before drug administration. On the day of last urine collection, 
animals were anesthetized with sodium pentobarbital (50 mg/kg) by an 
intraperitoneal injection, and then blood samples were collected via the 
abdominal aorta. Plasma levels of total cholesterol, triglyceride, albumin, total 
protein, and plasma and urine levels of creatinine were measured, and the Ccr 
was calculated. 
3.3.3.2 Effects of losartan and Íerapamil on nephrosis in young Dahl/S rats 
A total of 24 Dahl/S rats aged 4 weeks were divided into three groups and were 
daily given either vehicle, losartan (10 mg/kg), or verapamil (60 mg/kg) for 15 
days from the age of 5 weeks. Urine and blood collection, and measurements of 
SBP were performed following the same procedure as described above. 
3.3.3.3. Effect of imidapril on nephrosis in mature Dahl/S rats 
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A total of 16 Dahl/S rats aged 12 weeks were divided into two groups and were 
daily given either vehicle or imidapril (2 mg/kg) for 22 days from the age of 13 
weeks. Eight age-matched Dahl/R rats were given vehicle and served as a 
reference group. The 24-h urine collection was performed 5 days before and 1, 8, 
15 and 22 days after the start of drug administration. Systolic blood pressure 
was measured 3 days before and 4 and 11 days after the start of drug 
administration. On the day of last urine collection, animals were anesthetized, 
and then blood samples were collected as described above. Then the left kidney 
was removed for the histological examination.. 
3.3.3.4 Measurements 
Blood samples were placed in heparin-containing tubes on ice, and plasma 
samples were obtained by centrifugation (2500 rpm, 15 min, 4℃). The creatinine 
concentration in plasma and urine was measured by an enzymatic method 
(Creatinizyme, Eiken, Tokyo, Japan), using an automatic analyzer (Hitachi705, 
Hitachi, Tokyo, Japan). Urinary protein concentration was determined by the 
pyrogallol red method (Micro TP-AR, Wako, Osaka, Japan), using an automatic 
analyzer. Plasma levels of total cholesterol, triglyceride, albumin and total 
protein were measured by routine methods, using an automatic analyzer. 
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3.3.3.5 Histological examination 
Each kidney specimen was fixed in phosphate-buffered 10% formalin and 
dehydrated with ethanol. The tissues were then embedded in paraffin and 
sectioned. The sections were stained with the PAS reagent for light microscopic 
examination. The percentage of glomeruli with lesions was determined by blind 
observation. 
3.3.3.6 Statistical analysis 
Data are expressed as the means ± S.E.M. Analysis of variance followed by 
Dunnett’s test was used for comparisons between data for the control Dahl/S 
rats in the experiments with young Dahl/S rats. Unpaired t-test was used for data 
obtained for mature Dahl/S rats. A P-value less than 0.05 were considered to be 
statistically significant. The values for Dahl/R rats are shown as a reference, but 
were not included in the statistical analysis. 
 
3.4 Results 
3.4.1 Effects of imidapril and methylprednisolone on nephrosis in young Dahl/S 
rats 
The time courses of changes in body weight, UproV, and SBP are shown in 
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Figure 3.1. Control Dahl/S rats developed mild hypertension and marked 
proteinuria during the experimental periods. Imidapril inhibited both the 
hypertension and the increase in UproV in a dose-dependent manner. 
Methylprednisolone did not affect the development of proteinuria or hypertension, 
but significantly inhibited the increase in body weight. Plasma chemistry values 
and creatinine clearance are shown in Table 3.1. Control Dahl/S rats had high 
levels of total cholesterol and triglyceride and low levels of albumin and total 
protein. Treatment with imidapril at a dose of 2 mg/kg significantly lowered the 
concentration of total cholesterol and triglyceride, and elevated the level of total 
protein and albumin. Methylprednisolone suppressed the plasma level of total 
cholesterol but increased the triglyceride level. Ccr was not affected by these 
drugs. 
3.4.2 Effects of losartan and Íerapamil on nephrosis in young Dahl/S rats 
The time courses of changes in body weight, UproV, and SBP are shown in 
Figure 3.2. Losartan and verapamil similarly suppressed the increase in SBP. 
Losartan inhibited the development of proteinuria. In contrast, verapamil 
inhibited UproV only on the 1st day, but not on the 8th and 15th days after the 
start of administration. Verapamil caused a slight but significant suppression of 
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the increase in body weight. Plasma chemistry values and Ccr are shown in 
Table 3.2. Losartan significantly elevated the plasma albumin level. Verapamil 
significantly elevated the plasma total cholesterol level and Ccr. Ccr was not 
affected by losartan. 
3.4.3 Effect of imidapril on nephrosis in mature Dahl/S rats 
The time courses of changes in body weight, UproV, and SBP are shown in 
Figure 3.3. Imidapril decreased UproV and SBP. Plasma chemistry values and 
Ccr were not affected by imidapril (Table 3.3). Hyaline droplets and hypertrophy 
of podocytes were frequently seen in some glomeruli, and adhesion of the 
glomerulus to Bowman’s capsule was less frequently observed in control Dahl/S 
rats (Figure 3.4). Imidapril significantly decreased the incidence of these 
glomerular lesions (Figure 3.5A). The percentage of disordered glomeruli was 
significantly correlated with the values of UproV in Dahl/S rats (Figure 3.5B). 
 
3.5 Discussion 
This is the first report that drug treatment attenuates the development of 
spontaneous nephrosis in Dahl/S rats fed on a normal salt diet. There was 
marked proteinuria in 4-week old Dahl/S rats. Other investigators demonstrated 
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that Dahl/S rats showed proteinuria at the same age (48). The average absolute 
daily urinary excretion of protein at 4, 7, 12 and 16 weeks of age in control 
Dahl/S rats was 10, 89, 78 and 125 mg/day, respectively. Proteinuria in Dahl/S 
rats became steady after 7 weeks of ages. The 7-week old Dahl/S rats had 
abnormal plasma chemistry values, including high levels of total cholesterol and 
triglyceride, and low levels of albumin and total protein. Furthermore, I observed 
glomerular lesions in 16-week old Dahl/S rats. These changes were mild, but 
similar to those in patients with nephrosis. Thus, Dahl/S rats spontaneously 
develop nephrosis from a young age. 
Imidapril decreased proteinuria and normalized plasma chemistry variables in 
young Dahl/S rats. An AT-1 receptor antagonist, losartan, also inhibited the 
development of nephrosis in Dahl/S rats, like imidapril. The data suggest that 
angiotensin II is one of the causes and/or malignant factors in spontaneous 
nephrosis in Dahl/S rats. I did not measure plasma angiotensin II levels in this 
study. 
There is a report that serum angiotensin II levels of Dahl/S rats without sodium 
loading are the same as those of Dahl/R rats, but glomerular angiotensin II 
receptor density in Dahl/S rats is higher than that in Dahl/R rats Bouhnik and 
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Sahlgren (54, 55) reported that plasma renin activity and plasma angiotensin II 
concentration in Dahl/S rats tended to be lower than those in Dahl/R rats. 
Further studies on glomerular angiotensin II receptors are required to make clear 
the relationship between spontaneous nephrosis in Dahl/S rats and angiotensin 
II. 
Verapamil, a Ca2+ channel blocker, prevented the development of mild 
systemic hypertension but not proteinuria. These results suggest that imidapril 
and losartan attenuate the development of nephrosis by mechanisms other than 
systemic hypotension. In patients with proteinuria, angiotensin-converting 
enzyme inhibition decreases proteinuria independently of the decrease in 
systemic blood pressure (56). In remnant kidney rats, a Ca2+ channel blocker 
that decreased blood pressure to the same extent as an angiotensin-converting 
enzyme inhibitor failed to suppress proteinuria (57). Dahl/S rats fed on a high 
salt diet develop severe hypertension and renal damage (47). Prevention of the 
hypertension by nifedipine in salt-loaded Dahl/S rats reduces renal 
morphological changes (58). However, spontaneous nephrosis in Dahl/S rats is 
different from hypertension-induced renal damage because I could not observe 
any morphological changes typical of hypertensive renal impairment, such as 
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arteriolosclerosis, in this study. 
On the day after the start of drug administration, verapamil decreased 
proteinuria temporarily (Figure 3.2). There is a report that a decrease in blood 
pressure initiates the antiproteinuric effect of ACE inhibition in patients with renal 
disease (59). The transient reduction of proteinuria produced by imidapril or 
verapamil may result in part from the fall in blood pressure. A sustained 
attenuation of proteinuria requires inhibition of the renin–angiotensin system. 
The increase in Ccr elicited by verapamil suggests the possibility that this 
compound causes hyperfiltration in the glomeruli (Table 3.2). I did not determine 
single nephron hemodynamics. ACE inhibition, however, may not affect 
glomerular filtration in Dahl/S rats adversely. It has been reported that an ACE-I 
reduces glomerular filtration pressure but that a Ca2+ channel blocker dose not 
(60). In mature Dahl/S rats, imidapril suppressed mild hypertension and 
proteinuria, but failed to normalize plasma chemistry variables. The reason was 
that Dahl/S rats treated with imidapril still leaked a certain amount of protein into 
the urine. Imidapril, however, did ameliorate glomerular lesions. To evaluate 
glomerular damages, scoring methods have often been used (61). In this study, 
60–85% of glomeruli in control Dahl/S rats did not have significant histological 
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changes: typical glomerular lesions were the accumulation of hyaline droplets in 
podocytes (Figure 3.4). The changes in podocytes indicate that there was an 
increase in the glomerular filtration of protein. Glomerular damage, such as 
increase in mesangial matrix material or glomerulosclerosis, which are 
well-known changes in Dahl/S rat fed on a high-salt diet (61), was not frequently 
observed in this study. I, therefore, used the incidence of disordered glomeruli to 
determine glomerular lesions. There was a positive correlation between UproV 
and the incidence of glomerular lesions in mature Dahl/S rats. Proteinuria and 
glomerular lesions are closely associated in Dahl/S rats. It has been reported 
that the prevention of proteinuria by an ACE-I is important to renal protection in 
the adriamycin nephrosis rat (62). 
Abnormalities of lipid metabolism in Dahl/S rats have been demonstrated 
(50-53). Hirano et al. (51) reported abnormal properties of lipoprotein in Dahl/S 
rats. Probucol treatment in Dahl/S rats fed on a normal sodium diet decreased 
high-density lipoprotein cholesterol levels, but it could not correct proteinuria and 
hypoalbuminemia (63). In this study, imidapril treatment resulted in the 
suppression of proteinuria and in a reduction of hypercholesterolemia and 
hypertriglycemia in young Dahl/S rats. The findings indicate the possibility that 
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the abnormal lipid metabolism inDahl/S rats is primarily caused by spontaneous 
nephrosis. 
The development of nephrosis in Dahl/S rats was resistant to 
methylprednisolone, which is widely used in patients with proteinuria. I think that 
the dosage of methylprednisolone was enough because methylprednisolone 
increased the plasma level of triglyceride and suppressed the gain in body 
weight, which are common side effects of glucocorticoids (64). Nephrosis in 
Dahl/S rats is different from immunemediated glomerulonephritis. ACE-Is can be 
used to treat some aspects of steroid-resistant nephrosis. 
In summary, Dahl/S rats developed nephrosis without sodium loading. Imidapril 
attenuated the development of nephrosis and renal glomerular lesions in Dahl/S 
rats. Angiotensin II may play an important role in the development of 
spontaneous nephrosis in Dahl/S rats. 
 
3.6 Publication 
 The study in this chapter was published as “Involvement of angiotensin II in 
development of spontaneous nephrosis in Dahl salt-sensitive rats” in the 
European Journal of Pharmacology, 1998, 362: 213-9. 
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3.7 Figures and tables  
 
Figure 3.1 Effects of imidapril and methylprednisolone (MP) on urinary protein 
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excretion (UproV), systolic blood pressure (SBP), and body weight in young 
Dahl/S rats. Data are expressed as the means ± S.E.M. n=8. *P<0.05 and 
**P<0.01 as compared with corresponding Dahl/S control values by Dunnett’s 
test. Dahl/R: Dahl salt-resistant rats. 
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Figure 3.2 Effects of losartan and verapamil on urinary protein excretion (UproV), 
systolic blood pressure (SBP), and body weight in young Dahl/S rats. Data are 
expressed as the means ± S.E.M. n=8. **P<0.01 as compared with 
corresponding Dahl/S control values by Dunnett’s test. 
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Figure 3.3 Effects of imidapril on urinary protein excretion (UproV), systolic blood 
pressure (SBP), and body weight in mature Dahl/S rats. Data are expressed as 
the means ± S.E.M. n=8. *P<0.05 and **P<0.01 as compared with 
corresponding Dahl/S control values by unpaired t-test. Dahl/R: Dahl 
salt-resistant rats. 
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Figure 3.4 Light micrographs of typical glomerular lesions in 16-week old Dahl/S 
rats (periodic acid–Schiff reagent stain, bar: 25 mm) A: There are numerous 
hyaline droplets and hypertrophic podocytes in the glomerular tuft. B: The 
glomerulus is partially adhered to the Bowman’s capsule, causing a segmental 
sclerosis. 
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Figure 3.5 Effect of imidapril on glomerular lesions (A) and correlation between 
urinary protein excretion (UproV) and glomerular lesions (B) in 16-week old 
Dahl/S rats. Data are expressed as the means ± S.E.M. n=8. *P<0.05 as 
compared with corresponding Dahl/S control values by unpaired t-test. Dahl/R: 
Dahl salt-resistant rats.
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Table 3.1 Effects of imidapril and methylpredonisolone on plasma concentration of total cholesterol (CHO), triglyceride (TG), 
total protein (TP) and albumin (ALB), and creatinine clearance (Ccr) in 7-week old Dahl/S rats 
 
Values are the means ± S.E.M. n=8. aP<0.05 and bP<0.01 as compared with corresponding Dahl/S control values by 
Dunnett’s test. c Dahl salt-resistant rats and d methylpredonisolone. 
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Table 3.2 Effects of losartan and verapamil on plasma concentration of total cholesterol (CHO), triglyceride (TG), total protein 
(TP) and albumin (ALB), and creatinine clearance (Ccr) in 7-week old Dahl/S rats 
 
Values are the means ± S.E.M. n=8. aP<0.05 and bP<0.01 as compared with corresponding Dahl/S control values by 
Dunnett’s test. 
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Table 3.3 Effects of imidapril on plasma concentration of total cholesterol (CHO), triglyceride (TG), total protein (TP) and 
albumin (ALB), and creatinine clearance (Ccr) in 16-week old Dahl/S rats 
 
Values are the means ± S.E.M. n=8. aDahl salt-resistant rats.
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Concluding Remarks 
There are a lot of studies about the ACE-I since its first clinical appearance in 
1981. ACE-I was approved for the systemic hypertension primarily. The first 
report of its renoprotective effects was brought up using systemic hypertensive 
rats (65). After continuous studies about renoprotective effects of ACE-I, some 
ACE-Is included in imidapril approved for diabetic nephropathy in the late 1990’s 
or early 2000’s. In 1994, the first AT-1 receptor blocker was approved for the 
systemic hypertension. Since then, the interest of studies on renin-angiotensin 
system sifted to using AT-1 receptor blockers instead of ACE-Is in both area of 
basic and clinical science. It must be caused the simple mechanisms of AT-1 
receptor blockers, while the ACE is known to have broad substrate specificity 
(66). The ACE-I is a very classical drug, however, its pharmacological 
mechanisms still not clear enough. 
This study demonstrated that an ACE-I, imidapril has renoprotective effects in 
animals with albuminuria / proteinuria both of diabetic and non-diabetic 
conditions. Its renoprotection may be included following actions of imidapril: 
1) inhibition of systemic renin-angiotensin system which produce lowering 
systemic blood pressure, 
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2) inhibition of renal renin-angiotensin system which lead protection of renal 
heparin sulfate, and correction of renal hyperfiltration, 
3) the other mechanisms (?) 
The chapter 1 and 3 indicated that lowering systemic blood pressure should be 
important, but the only vasodilation is not enough to produce renoprotective 
effects. Additionally, imidapril showed renoprotective effect without lowering 
systemic blood pressure in the chapter 2. These findings suggest that 
renoprotective effcts of imidapril exist beyond the antihypertensive effects. The 
antihypertensive effects of ACE-Is based on the inhibition of systemic 
renin-angiotensin system, and additionally facilitates of vasodilation by 
bradykinin. Inhibition of the renal local renin-angiotensin system might be 
important in the renoprotective effects of imidapril. 
Major parts of renoprotective effects of imidapril may produce as direct action to 
the renal renin-angiotensin system. The balance of contribution to renoprotective 
effects between antihypertensive effects and inhibition the renal local 
renin-angiotensin system should be different from drugs, even in the ACE-Is. 
Imidapril showed stronger inhibition of the renal ACE activity than another ACE-I, 
so that the effects may strongly contribute renoprotective effects of imidapril. The 
 - 72 - 
 
renal renin-angiotensin system are important to maintain the glomerular 
structures (67). The chapter 2 demonstrated that imidapril suggested that 
protected haparan sulfate, which is one of the glomerular basement membrane 
components. These facts indicated that the over works of renal 
renin-angiotensin system might injure glomerular structures. 
Renal glomerular hyperfiltration is one of the typical symptoms in diabetes. 
Imidapril showed correction of hyperfiltration in the chapter 2, but did not affect in 
the chapter 1 and 3. Imidapril increased renal blood flow and Ccr in 
volume-loaded dogs (68). Glomerular filtration is controlled by a complicated 
procedure, for example blood pressure, hydration state, renin-angiotensin 
system, and so on. Therefore the effect of imidapril against renal filtration might 
be variable. In the clinical use of ACE-Is, acute renal failure is a considerable 
adverse effect (69). The facts proved that the renal renin-angiotensin system 
participates the fundamental function of the kidney both of normal and disease 
states. Therefore the correction of hyperfiltration states accompanied with 
diabetes would be useful for the renoprotective effects. In the chapter 3, 
verapamil, which did not reduce proteinuria enough, increased Ccr. Excess 
glomerular filtration might be wrong even in the non-diabetic condition. 
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The chapter 3 suggested that proteinuria closely related with glomerular 
damage. Throughout this study, I could not resolve whole mechanisms of 
reducing albminuria or proteinuria by imidapril, however, these effects of 
imidapril should strongly contribute to protect the renal glomerular structures. 
 
Figure  Angiotensin-converting enzyme inhibitors (ACE-Is) prevents kidney 
disease by inhibiting both of the systemic and renal renin-angiotensin system. 
 
Considering these findings, imidapril produce its renoprotective effects through 
both functional and structural improvement in the kidney. Furthermore, imidapril 
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exhibits its renoprotective effects not only diabetic conditions but non-diabetic 
nephrosis.  
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